Clinical trial NCT01185314: To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Official title: A Molecular Epidemiology Study in Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC) of Adeno Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Non Small Cell Lung Cancer
Keywords: NSCLC, EGFR mutation
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-08-19
Enrollment: 1270
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The purpose of this study is to study the changes in protein in lung cells of Asian patients with advanced non small cell lung cancer.

Detailed description: A molecular epidemiology study in Asian patients with advanced NSCLC of adeno histology to assess EGFR mutation status.

Eligibility criteria: Inclusion Criteria:

* Histological or cytologically confirmed advanced Non small cell lung cancer of adeno histology NSCLC treatment naive Availability of cancer tissue or cytology sample

Exclusion Criteria:

* Involvement in the planning and/or conduct of the study Previous enrollment in the present study

Primary outcomes:
measure: EGFR mutation status of Asian patients with advanced NSCLC
timeFrame: Samples will be tested after informed consent. Mutation results will be available within 1-3 weeks.
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Research Site
state: Beijing
city: Guangzhou
country: China
facility: Research Site
state: Guangdong
city: Shijiazhuang
country: China
facility: Research Site
state: Hebei
city: Zhengzhou
country: China
facility: Research Site
state: Henan
city: Wuhan
country: China
facility: Research Site
state: Hubei
city: Changchun
country: China
facility: Research Site
state: Jilin
city: Shenyang
country: China
facility: Research Site
state: Liaoning
city: Jinan
country: China
facility: Research Site
state: Shandong
city: Shanghai
country: China
facility: Research Site
state: Shanghai
city: Taiyuan
country: China
facility: Research Site
state: Shanxi
city: Chengdu
country: China
facility: Research Site
state: Sichuan
city: Tianjin
country: China
facility: Research Site
state: Tianjin
city: Hong Kong
country: Hong Kong
facility: Research Site
city: Rohini
country: India
facility: Research Site
state: Delhi
city: Vadodara
country: India
facility: Research Site
state: Gujarat
city: Kochi
country: India
facility: Research Site
state: Kerala
city: Mumbai
country: India
facility: Research Site
state: Maharashtra
city: Pune
country: India
facility: Research Site
state: Maharashtra
city: Chennai
country: India
facility: Research Site
city: Kolkata
country: India
facility: Research Site
city: Cebu City
country: Philippines
facility: Research Site
city: Manila City
country: Philippines
facility: Research Site
city: Pasay City
country: Philippines
facility: Research Site
city: Quezon City
country: Philippines
facility: Research Site
city: Taguig City
country: Philippines
facility: Research Site
city: Chiayi
country: Taiwan
facility: Research Site
city: Kaohsiung
country: Taiwan
facility: Research Site
city: Taichung
country: Taiwan
facility: Research Site
city: Tainan
country: Taiwan
facility: Research Site
city: Taipei
country: Taiwan
facility: Research Site
city: Tao-Yuan
country: Taiwan
facility: Research Site
city: Bangkok
country: Thailand
facility: Research Site
city: Chiang Mai
country: Thailand
facility: Research Site
city: Songkla
country: Thailand
facility: Research Site
city: Hanoi
country: Vietnam
facility: Research Site
city: Ho Chi Minh City
country: Vietnam
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: Guy Yeoman, MBBS, MFPM
role: STUDY_DIRECTOR
affiliation: AstraZeneca Taiwan
name: Robin Meng, MD, PhD
role: STUDY_CHAIR
affiliation: National Taiwan University College of Medicine
name: Yang Pan-Chyr, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: